On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first drug with both an AI-discovered target and an AI-designed molecule to reach Phase III. We break down the TNIK story, the Phase IIa data published in Nature Medicine, the provocative aging-clock signals in Nature Biotechnology, and what this milestone really proves - and doesn't - about AI drug discovery. Produced by Dr. Jake Chen.

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör Dr. Jake Chen. Innehållet i podden är skapat av Dr. Jake Chen och inte av, eller tillsammans med, Poddtoppen.